-
Signature
-
/s/ Vijay Iyer, Attorney-in-Fact
-
Issuer symbol
-
BKNG
-
Transactions as of
-
17 Nov 2025
-
Net transactions value
-
-$2,003,074
-
Form type
-
4
-
Filing time
-
19 Nov 2025, 07:35:06 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Fogel Glenn D |
CEO AND PRESIDENT, Director |
BOOKING HOLDINGS INC., 800 CONNECTICUT AVENUE, NORWALK |
/s/ Vijay Iyer, Attorney-in-Fact |
19 Nov 2025 |
0001516908 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
BKNG |
Common Stock |
Sale |
$48,738 |
-10 |
-0.05% |
$4873.79 |
22,141 |
17 Nov 2025 |
Direct |
F1, F2 |
| transaction |
BKNG |
Common Stock |
Sale |
$48,849 |
-10 |
-0.05% |
$4884.87 |
22,131 |
17 Nov 2025 |
Direct |
F1 |
| transaction |
BKNG |
Common Stock |
Sale |
$48,924 |
-10 |
-0.05% |
$4892.40 |
22,121 |
17 Nov 2025 |
Direct |
F1 |
| transaction |
BKNG |
Common Stock |
Sale |
$49,086 |
-10 |
-0.05% |
$4908.60 |
22,111 |
17 Nov 2025 |
Direct |
F1 |
| transaction |
BKNG |
Common Stock |
Sale |
$49,757 |
-10 |
-0.05% |
$4975.74 |
22,101 |
17 Nov 2025 |
Direct |
F1 |
| transaction |
BKNG |
Common Stock |
Sale |
$49,968 |
-10 |
-0.05% |
$4996.76 |
22,091 |
17 Nov 2025 |
Direct |
F1 |
| transaction |
BKNG |
Common Stock |
Sale |
$149,977 |
-30 |
-0.14% |
$4999.23 |
22,061 |
17 Nov 2025 |
Direct |
F1, F3 |
| transaction |
BKNG |
Common Stock |
Sale |
$100,061 |
-20 |
-0.09% |
$5003.05 |
22,041 |
17 Nov 2025 |
Direct |
F1 |
| transaction |
BKNG |
Common Stock |
Sale |
$50,042 |
-10 |
-0.05% |
$5004.23 |
22,031 |
17 Nov 2025 |
Direct |
F1 |
| transaction |
BKNG |
Common Stock |
Sale |
$100,189 |
-20 |
-0.09% |
$5009.46 |
22,011 |
17 Nov 2025 |
Direct |
F1, F4 |
| transaction |
BKNG |
Common Stock |
Sale |
$100,252 |
-20 |
-0.09% |
$5012.58 |
21,991 |
17 Nov 2025 |
Direct |
F1, F5 |
| transaction |
BKNG |
Common Stock |
Sale |
$150,473 |
-30 |
-0.14% |
$5015.75 |
21,961 |
17 Nov 2025 |
Direct |
F1, F6 |
| transaction |
BKNG |
Common Stock |
Sale |
$50,172 |
-10 |
-0.05% |
$5017.24 |
21,951 |
17 Nov 2025 |
Direct |
F1 |
| transaction |
BKNG |
Common Stock |
Sale |
$50,208 |
-10 |
-0.05% |
$5020.80 |
21,941 |
17 Nov 2025 |
Direct |
F1 |
| transaction |
BKNG |
Common Stock |
Sale |
$50,242 |
-10 |
-0.05% |
$5024.25 |
21,931 |
17 Nov 2025 |
Direct |
F1 |
| transaction |
BKNG |
Common Stock |
Sale |
$100,520 |
-20 |
-0.09% |
$5025.98 |
21,911 |
17 Nov 2025 |
Direct |
F1, F7 |
| transaction |
BKNG |
Common Stock |
Sale |
$100,546 |
-20 |
-0.09% |
$5027.28 |
21,891 |
17 Nov 2025 |
Direct |
F1, F8 |
| transaction |
BKNG |
Common Stock |
Sale |
$50,281 |
-10 |
-0.05% |
$5028.11 |
21,881 |
17 Nov 2025 |
Direct |
F1 |
| transaction |
BKNG |
Common Stock |
Sale |
$50,301 |
-10 |
-0.05% |
$5030.11 |
21,871 |
17 Nov 2025 |
Direct |
F1 |
| transaction |
BKNG |
Common Stock |
Sale |
$150,999 |
-30 |
-0.14% |
$5033.31 |
21,841 |
17 Nov 2025 |
Direct |
F1, F9 |
| transaction |
BKNG |
Common Stock |
Sale |
$151,059 |
-30 |
-0.14% |
$5035.30 |
21,811 |
17 Nov 2025 |
Direct |
F1, F10 |
| transaction |
BKNG |
Common Stock |
Sale |
$50,362 |
-10 |
-0.05% |
$5036.25 |
21,801 |
17 Nov 2025 |
Direct |
F1 |
| transaction |
BKNG |
Common Stock |
Sale |
$50,378 |
-10 |
-0.05% |
$5037.77 |
21,791 |
17 Nov 2025 |
Direct |
F1 |
| transaction |
BKNG |
Common Stock |
Sale |
$100,798 |
-20 |
-0.09% |
$5039.89 |
21,771 |
17 Nov 2025 |
Direct |
F1, F11 |
| transaction |
BKNG |
Common Stock |
Sale |
$100,893 |
-20 |
-0.09% |
$5044.64 |
21,751 |
17 Nov 2025 |
Direct |
F1, F12 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: